Eye diseases often develop asymptomatically for many years. ICTER scientists have developed the f-ORG technique, which ...

Privately-held Ashvattha Therapeutics, a Californian firm advancing a new class of nanomedicine therapeutics that traverse ...

Needham initiated coverage on Ocular Therapeutix Inc (NASDAQ:OCUL), noting the company’s lead asset, Axpaxli, an ...

Read the Market Summary Here:- https://reportocean.com/industry-verticals/sample-request?report_id=bwcc18604 ...

Professor Yit Yang discussed how pathology identified in retinal layers after an OCT scan can lead to diagnosis in his ...

Topline clinical data of the confirmatory registrational study GLOW2 expected in 1Q 2026. <li /> GLOW2 study design mirrors GLOW1 study, ...

Topline clinical data of the confirmatory registrational study GLOW2 expected in 1Q 2026. GLOW2 study design mirrors GLOW1 study, which met primary endpoint and ...

Kodiak reports completing patient enrollment in its late-stage study evaluating tarcocimab for diabetic retinopathy.

Fintel reports that on March 11, 2025, Needham initiated coverage of Ocular Therapeutix (NasdaqGM:OCUL) with a Buy ...

Kodiak Sciences (KOD) announced that it has completed enrollment in its GLOW2 Phase 3 clinical trial of tarcocimab tedromer in patients with ...

"This is a historic moment for 4DMT as we become a Phase 3 company following our initiation of the 4FRONT-1 clinical trial,” said David Kirn, M.D., Co-founder and Chief Executive Officer of 4DMT.

While it is easier to advise people to not sit for long hours in front of their screens, for those who work on a computer, it is a difficult task to achieve. Sitting for a prolonged time in front of ...